Live webcast fireside chat on Monday, March 18th at 9:00 AM PT
HOUSTON, March 12,
2024 /PRNewswire/ -- Moleculin Biotech, Inc.,
(Nasdaq: MBRX) (Moleculin or the Company), a clinical stage
pharmaceutical company with a broad portfolio of drug candidates
targeting hard-to-treat tumors and viruses, today announced
Jonathan Foster, Executive VP and
Chief Financial Officer of Moleculin will participate in a fireside
chat at the 36th Annual ROTH Conference on
March 18, 2024 at 9:00 AM PT.
In addition to the presentation, management will be available to
participate in one-on-one in-person meetings with qualified members
of the investor community who are registered to attend the
conference. For more information about the event, please visit
the conference website.
A live webcast of the fireside chat will be available on
the Events page in the Investors section of the Company's
website (moleculin.com). The webcast replay will be archived for 90
days following the event.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company with a growing pipeline, including Phase 2 clinical
programs, for hard-to-treat tumors and viruses. The Company's lead
program, Annamycin is a next-generation anthracycline designed to
avoid multidrug resistance mechanisms with little to no
cardiotoxicity. Annamycin is currently in development for the
treatment of acute myeloid leukemia (AML) and soft tissue sarcoma
(STS) lung metastases.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also
engaged in the development of a portfolio of antimetabolites,
including WP1122 for the potential treatment of COVID-19 and other
viruses, as well as cancer indications including brain tumors,
pancreatic and other cancers.
For more information about the Company, please
visit www.moleculin.com and connect on Twitter,
LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-36th-annual-roth-conference-302086104.html
SOURCE Moleculin Biotech, Inc.